Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.
Coadministration of kappa-opioid receptor agonists (kappa-agonists) with cocaine prevents alterations in dialysate dopamine (DA) concentration in the nucleus accumbens (Acb) that occur during abstinence from repeated cocaine treatment. Quantitative microdialysis was used to determine the mechanism producing these effects. Rats were injected with cocaine (20 mg/kg, i.p.), or saline, and the selective kappa-agonist U-69593 (0.32 mg/kg, s.c.), or vehicle, once daily for 5 d. Extracellular DA concentration (DA(ext)) and extraction fraction (E(d)), an indirect measure of DA uptake, were determined 3 d later. Repeated cocaine treatment increased E(d), whereas repeated U-69593 treatment decreased E(d), relative to controls. Coadministration of both drugs yielded intermediate E(d) values not different from controls. In vitro DA uptake assays confirmed that repeated U-69593 treatment produces a dose-related, region-specific decrease in DA uptake and showed that acute U-69593 administration increases DA uptake in a nor-binaltorphimine reversible manner. Repeated U-69593 also led to a decrease in [(125)I]RTI-55 binding to the DA transporter (DAT), but did not decrease total DAT protein. These results demonstrate that kappa-opioid receptor activation modulates DA uptake in the Acb in a manner opposite to that of cocaine: repeated U-69593 administration decreases the basal rate of DA uptake, and acute U-69593 administration transiently increases DA uptake. kappa-agonist treatment also alters DAT function. The action of kappa-agonists on DA uptake or DAT binding, or both, may be the mechanism(s) mediating the previously reported "cocaine-antagonist" effect of kappa-opioid receptor agonists.
Thompson
A C
AC
Behavioral Neuroscience Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA. act2@buffalo.edu
Zapata
A
A
Justice
J B
JB
Vaughan
R A
RA
Sharpe
L G
LG
Shippenberg
T S
TS
D000704:Analysis of Variance; D000818:Animals; D001345:Autoradiography; D044482:Benzeneacetamides; D002352:Carrier Proteins / Q000378:metabolism; D003042:Cocaine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D003342:Corpus Striatum / Q000737:chemistry / Q000378:metabolism; D004298:Dopamine / Q000032:analysis / Q000493:pharmacokinetics*; D050483:Dopamine Plasma Membrane Transport Proteins; D004334:Drug Administration Schedule; D004336:Drug Antagonism; D005110:Extracellular Space / Q000737:chemistry / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007457:Iodine Radioisotopes; D016014:Linear Models; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D017551:Microdialysis; D009271:Naltrexone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009419:Nerve Tissue Proteins; D009714:Nucleus Accumbens / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism*; D011759:Pyrrolidines / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000378:metabolism*
D044482:Benzeneacetamides; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D007457:Iodine Radioisotopes; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; C493216:Slc6a3 protein, rat; C051844:norbinaltorphimine; D009271:Naltrexone; D003042:Cocaine; C045444:U 69593; D004298:Dopamine